Chamber bitter
Phyllanthus urinaria
Phyllanthus urinaria, a plant traditionally used in various Asian and African herbal practices but with no specific recorded traditional uses, has shown promise in scientific research. Studies have indicated that its n-hexane fraction demonstrated moderate cytotoxicity against HeLa cells, suggesting potential anti-cervical cancer activity. Additionally, a polyherbal formulation containing Phyllanthus urinaria and Adhatoda vasica showed significant inhibition of α-amylase and α-glucosidase in mice, potentially reducing blood glucose levels and increasing insulin protein expression, which may be beneficial for diabetes management. A review suggests that Phyllanthus species, including P. urinaria, have potential in diabetes intervention based on their phytochemical profiles and antidiabetic properties; however, clinical evidence remains limited. PU has also been found to mitigate cisplatin-induced acute kidney injury by reducing inflammation, apoptosis, and oxidative stress. No major safety issues or recorded drug interactions are associated with Phyllanthus urinaria at this time.
- Best evidence
- D
- Cautions
- —
Informational only. Traditional use does not mean proven effectiveness. Evidence and safety vary — check the cited sources.
What the science says
- This review highlights the potential of Phyllanthus urinaria in diabetes intervention, supported by its antidiabetic properties and bioactive compounds, though clinical evidence is limited.
- PU showed potential in mitigating cisplatin-induced acute kidney injury by reducing inflammation, apoptosis, and oxidative stress.
- The n-hexane fraction of Phyllanthus urinaria exhibited moderate cytotoxicity against HeLa cells, suggesting potential anti-cervical cancer activity.
- The study found that a polyherbal formulation of Phyllanthus urinaria and Adhatoda vasica showed significant inhibition of α-amylase and α-glucosidase, reducing blood glucose levels and increasing insulin protein expression in mice.
Frequently asked questions
What is Chamber bitter?
Chamber bitter (Phyllanthus urinaria) is a plant documented in FolkKB's traditional-medicine reference, drawn from sourced literature and cross-checked against the evidence.
What does the scientific evidence say about Chamber bitter?
4 sourced findings are recorded for Chamber bitter; the strongest carries evidence grade D. For example: This review highlights the potential of Phyllanthus urinaria in diabetes intervention, supported by its antidiabetic properties and bioactive compounds, though clinical evidence is limited.
How strong is the evidence for Chamber bitter?
The strongest finding for Chamber bitter carries evidence grade D — preliminary or traditional. Grades run A (strongest) to D (preliminary or traditional).
Is Chamber bitter safe? What are the side effects?
No major safety issues are recorded for Chamber bitter in our sources, but the data may be incomplete. Consult a qualified professional before use.
Does Chamber bitter interact with medications?
No drug interactions are recorded for Chamber bitter in our sources. This does not rule them out — check with a pharmacist.
Is Chamber bitter a proven treatment?
No. FolkKB is informational only. Traditional use and early findings are not proof of efficacy or safety — consult a qualified professional and never self-treat.
Sources
- T2 Therapeutic Effects of Phyllanthus urinaria L on Cisplatin-Induced Acute Kidney Injury: Anti-Inflammatory, Anti-Apoptotic, and Anti-Oxidative Action. literature abstract metadata
- T2 Unlocking the Potential of Phyllanthus Species From Traditional Knowledge to Clinical Trials: An Updated Review of Metabolomics Approach in Diabetes Intervention. literature abstract metadata
- T2 DPP4 and Insulin Protein: Drug Targets for a Formulated Polyherbal Combination of Phyllanthus urinaria L. and Adhatoda vasica Nees Against HFD-STZ-Induced TIIDM in Swiss Albino Mice. literature abstract metadata
- T2 Computational and Cytotoxicity Evaluation of Phyllanthus Urinaria-Derived Compounds as Potential Anti-Cervical Cancer Agents via HPV-16 E6 Oncoprotein Inhibition. literature abstract metadata